Anxiety Disorder

Generalized Anxiety Disorder (GAD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Generalized Anxiety Disorder (GAD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Generalized Anxiety Disorder (GAD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Ma...

$2,000.00

Obsessive-Compulsive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 08 Apr 2022 11:35:28 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking, and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Drugs in Developmen...

$2,000.00

Generalized Anxiety Disorder - Pipeline Insight, 2021

Wed, 08 Sep 2021 15:57:35 +0000

DelveInsight’s, “Generalized Anxiety Disorder – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Generalized Anxiety Disorder Understanding Generalized Anxiety Disorder: Overview Generalized anxiety disorder (or GAD) is marked by excessive, exaggerated anxiety and worry about everyday life events for no obvious reason. People with symptoms of generalized anxiety disorder tend to always expect disaster and can't stop worrying about health, money, family, work, or school. GAD is diagnosed when a person finds it difficult to control worry on more days than not for at least six months and has three or more symptoms. This differentiates GAD from worry that ...

$1,500.00

Generalized Anxiety Disorder (GAD) - Pipeline Insight, 2020

Thu, 15 Oct 2020 12:43:30 +0000

This “Generalized Anxiety Disorder (GAD) - Pipeline Insight, 2020” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Generalized Anxiety Disorder Understanding Generalized Anxiety Disorder (GAD): Overview Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. Peopl...

$1,500.00

Generalized Anxiety Disorder (GAD)- Market Insight, Epidemiology and Market Forecast -2030

Wed, 14 Oct 2020 15:56:15 +0000

DelveInsight’s ‘Generalized Anxiety Disorder (GAD)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the GAD, historical and forecasted epidemiology as well as the GAD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. The GAD market report provides current treatment practices, emerging drugs, GAD market share of the individual therapies, current and forecasted GAD market size from 2017 to 2030 segmented by seven major markets. The Report also covers current GAD treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2017–2030 Generalized Anxiety Disorder (GAD): Disease Understanding and Treatment Algorithm Generalized Anxiety Disorder Overview Generalized Anxiety Disorder (GAD) is characterized by persistent and exaggerated anxiety a...

$6,950.00

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guid...

$2,000.00

Obsessive-Compulsive Disorder - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H1 2019, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under d...

$2,000.00

Acute Stress Disorder Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acute Stress Disorder Global Clinical Trials Review, H2, 2018" provides an overview of Acute Stress Disorder clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Stress Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies t...

$2,500.00

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

Fri, 30 Nov 2018 11:36:19 +0000

Summary

This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.

PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.

OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unloc...

$3,995.00

Obsessive-Compulsive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 5-10 business days to complete. DelveInsight’s Obsessive-Compulsive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Obsessive-Compulsive Disorder forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Obsessive-Compulsive Disorder till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Obsessive-Compulsive Disorder market. • Identifying patient populations in the global “Obsessive-Compulsive Disordermarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Obse...

$4,950.00

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Major Depressive Disorder forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Major Depressive Disorder till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Major Depressive Disorder market. • Identifying patient populations in the global “Major Depressive Disordermarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Major Depressive Disorder...

$4,950.00

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets ...

$2,000.00

Obsessive-Compulsive Disorder - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H2 2016’, provides an overview of the Obsessive-Compulsive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical ...

$2,000.00

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

Thu, 15 Sep 2016 21:22:00 +0000

Summary

Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, compan...

$2,000.00

Obsessive-Compulsive Disorder Global Clinical Trials Review, H2, 2016

Thu, 15 Sep 2016 20:23:57 +0000

Summary

GlobalData's clinical trial report, “Obsessive-Compulsive Disorder Global Clinical Trials Review, H2, 2016" provides an overview of Obsessive-Compulsive Disorder clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effect...

$2,500.00

Oppositional Defiant Disorder (ODD) Global Clinical Trials Review, H2, 2016

Thu, 15 Sep 2016 20:23:57 +0000

Summary

GlobalData's clinical trial report, “Oppositional Defiant Disorder (ODD) Global Clinical Trials Review, H2, 2016" provides an overview of Oppositional Defiant Disorder (ODD) clinical trials scenario. This report provides top line data relating to the clinical trials on Oppositional Defiant Disorder (ODD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps t...

$2,500.00

Social Anxiety Disorders (SAD) Global Clinical Trials Review, H2, 2016

Thu, 15 Sep 2016 20:23:57 +0000

Summary

GlobalData's clinical trial report, “Social Anxiety Disorders (SAD) Global Clinical Trials Review, H2, 2016" provides an overview of Social Anxiety Disorders (SAD) clinical trials scenario. This report provides top line data relating to the clinical trials on Social Anxiety Disorders (SAD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an eff...

$2,500.00

Bipolar disorder (BPD) - Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

DelveInsight’s Bipolar disorder (BPD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Bipolar disorder (BPD) for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Bipolar disorder (BPD) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Bipolar disorder (BPD) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Bipolar disorder (BPD) market. • Identifying patient populations in the global Bipolar disorder (BPD) market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Bipolar disorder (BPD) therapeutics in each of the markets covered. • To understand the future...

$4,950.00

Attention-deficit/hyperactivity disorder (ADHD)- Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Attention-deficit/hyperactivity disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Attention-deficit/hyperactivity disorder (ADHD) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Attention-deficit/hyperactivity disorder (ADHD) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Attention-deficit/hyperactivity disorder (ADHD) market. • Identifying patient populations in the global “Attention-deficit/hyperactivity disorder (ADHD)market to improve product design, pricing, and launch plans. •...

$4,950.00

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

Fri, 10 Jun 2016 19:37:17 +0000

Summary

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a fiel...

$10,995.00

Obsessive-Compulsive Disorder - Pipeline Review, H1 2016

Sun, 29 May 2016 12:24:04 +0000

Summary

Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H1 2016’, provides an overview of the Obsessive-Compulsive Disorder pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical ...

$2,000.00

Anxiety Disorders - Pipeline Review, H1 2016

Sat, 28 May 2016 18:39:51 +0000

Summary

Global Markets Direct’s, ‘Anxiety Disorders - Pipeline Review, H1 2016’, provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, inve...

$2,000.00